Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in North America. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 in subjects with type 2 diabetes not achieving glycaemic targets on OADs (oral anti-diabetic drugs).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin aspart, insulin aspart protamine drug combination 30:70; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Isophane; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus for at least 12 months

• HbA1c between 7.5-14.5% (inclusive) at screening

• Insulin naïve

• An antidiabetic regimen that has been stable for at least 3 months prior to screening

• An antidiabetic regimen that includes a minimum of 2 OADs

Exclusion Criteria:

• Use of any insulin preparations within the past 6 months

• Active proliferative retinopathy or maculopathy requiring treatment within 6 months prior to screening